Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IMI becomes PreMD

This article was originally published in The Tan Sheet

Executive Summary

International Medical Innovations has changed its name to PreMD Inc., stating that the new name "better reflects our predictive medicine focus, achievements and growth direction," the firm announces Sept. 27. "The name PreMD describes the role the company's products fulfill: predicting disease at an early stage in order to prevent its progression, or from occurring at all," the company formerly known as IMI states. "Pre," when combined with "MD," suggests the early monitoring and management of one's health, and reflects PreMD's focus on empowering patients and doctors alike to preserve and promote total health and wellness." The company will trade shares on the American Stock Exchange under PME, effective Sept. 30, PreMD said. The firm also announced the launch of a new corporate website...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel